News | July 05, 2023
Biocon Biologics expands footprint in emerging markets
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
Laurus Labs has announced that the USFDA completed inspection of the formulations manufacturing facility Unit-2, APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh.
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
The observations primarily relate to the need for improving strategies for microbial control, enhancing quality oversight, augmenting the use of software applications & computerized tools
Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020
Globally, cervical cancer is the fourth most common cancer among women, with approximately 30,447 new cases diagnosed in Europe in 2020
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
Key takeaways of recent quarter & conference call highlights
Subscribe To Our Newsletter & Stay Updated
